Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2022 Earnings Results

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 4.48%

Arrowhead Pharmaceuticals reported a loss that was worse than expected, leading to a 4.48% drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's short-term performance. Management's focus on long-term strategies suggests they are prioritizing future growth over immediate results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	-177.78%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to long-term strategies without offering specific guidance.

Management did not provide specific details on revenue expectations.

The company is focusing on long-term growth despite current challenges.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 4.48%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 4.48%

Key numbers

Management commentary